Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study

Detalles Bibliográficos
Autores principales: Nelli, F., Giannarelli, D., Fabbri, A., Silvestri, M.A., Berrios, J. R. Giron, Virtuoso, A., Marrucci, E., Schirripa, M., Mazzotta, M., Onorato, A., Panichi, V., Topini, G., Pessina, G., Natoni, F., Signorelli, C., Chilelli, M.G., Primi, F., Ruggeri, E.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society for Medical Oncology. Published by Elsevier Ltd. 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993701/
https://www.ncbi.nlm.nih.gov/pubmed/35413398
http://dx.doi.org/10.1016/j.annonc.2022.04.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993701/
https://www.ncbi.nlm.nih.gov/pubmed/35413398
http://dx.doi.org/10.1016/j.annonc.2022.04.002

Ejemplares similares